Peregrine Pharmaceuticals | PPHM - Les Charges D'Exploitation



Les Charges D'Exploitation Changement Date
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Celldex Therapeutics USD 87.27M 511.09M 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
MannKind USD 119.64M 56.29M 2025-12
Merck USD 10.16B 558M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Novartis USD 9.8B 61M 2025-12
Novavax USD 126.2M 23.62M 2025-12
Repligen USD 177.94M 1.82M 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Xencor USD 81.86M 13.35M 2025-12